 |
|
|
| |
IMPAACT 2017 Adolescent/Parent Experiences with
LA Cabotegravir Plus Rilpivirine for HIV Treatment
|
| |
| |
CROI 2024 March 3-6 Denver
Elizabeth D. Lowenthal1,2, Jennifer Chapman2, Martina Zapata Vaca1, Shawn Ward3, Ryan Milligan3, Andres Camacho-Gonzalez4, Gaerolwe Masheto5, Cindy McCoig6, Andi Ace3, Rodica Van Solingen-Ristea7, Dwight Yin8, Sarah Buisson9, Carolyn Bolton Moore10, Aditya H. Gaur11, for the IMPAACT 2017 Team
1University of Pennsylvania, Philadelphia, PA, USA, 2Children's Hospital of Philadelphia, Philadelphia, PA, USA, 3Frontier Science and Technology Research Foundation, Inc, Amherst, NY, USA, 4Emory University, Atlanta, GA, USA, 5Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, 6ViiV Healthcare, Madrid, Spain, 7Janssen Research and Development, Beerse, Belgium, 8National Institute of Allergy and Infectious Diseases, Rockville, MD, USA, 9FHI 360, Bangkok, Thailand, 10Univsity of Alabama at Birmingham-Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, 11St Jude Children's Research Hospital, Memphis, TN, USA
|
| |
|
|
|
|
|
